TY  - JOUR
TI  - Determination of COVID-19 PCR positivity and mutation status in coronaVac
vaccinated individuals in Turkey
AB  - Background/aim: CoronaVac is an inactivated virus-based COVID-19 vaccine used in Turkey and approved for emergency use by the
World Health Organization (WHO). In this study, it was aimed to retrospectively evaluate the mutation status and clinical status in
individuals who received two doses of CoronaVac vaccine and were infected with COVID-19 at least two weeks after the second dose.
Materials and methods: 164 people were included in the study and COVID-19 diagnosis and mutation analyses were determined by
RT-PCR using the Bioseepdy SARS CoV-2 Double Gene RT-qPCR Kit and the Biospeedy SARS-CoV-2 Variant Plus kit in accordance
with the protocol determined by the manufacturer.
Results: 116 (70.7%) UK (Alpha, B.1.1.7) mutation and 3 (1.8%) South Africa (Beta, B.1.351), Brazil (Gamma, P.1) mutations were
determined in 164 double doses CoronaVac vaccinated patients; 45 (27.5%) patients were mutation negative. Nine patients (5.5%)
developed pneumonia. Eight patients (4.9%) had CT findings compatible with corona virus infection. Seven (4.3%) of the patients
received treatment in the intensive care unit, and 5 (3%) of the patients were intubated.
Conclusions: In conclusion, people who receive two doses of CoronaVac vaccine can be reinfected with mutant viruses, vaccine
significantly reduces the need for hospitalization, CT findings and intensive care.
AU  - Küçükakın Yaka, Saniye
AU  - Kaleli, İlknur
AU  - Öner, Sedef Zeliha
AU  - Sari, Tugba
AU  - Çalışkan, Ahmet
AU  - DÖNMEZ, BÜŞRA
AU  - Seçme, Mücahit
DO  - 10.55730/1300-0144.5344
PY  - 2022
JO  - Turkish Journal of Medical Sciences
VL  - 52
IS  - 3
SN  - 1300-0144
SP  - 541
EP  - 546
DB  - TRDizin
UR  - http://search/yayin/detay/536213
ER  -